CRISPR Therapeutics grants CMO 22,000 RSUs

Patel Naimish reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

Patel Naimish reported acquisition or exercise transactions in this Form 4 filing.

CRISPR Therapeutics AG reported that Chief Medical Officer Naimish Patel received a grant of 22,000 restricted stock units. Each unit represents one common share. The award was granted as compensation on May 29, 2026, and all 22,000 units are scheduled to vest on November 29, 2028, subject to the usual conditions.

Insights

Equity compensation analyst

Routine equity grant gives CRISPR CMO 22,000 RSUs vesting in 2028.

Chief Medical Officer Naimish Patel received 22,000 restricted stock units as a compensation award, not an open‑market purchase. Each RSU converts into one common share, aligning his incentives with shareholders over time.

The filing states that 100% of the RSUs vest on November 29, 2028, indicating a long-term retention and performance horizon. With total RSUs following the transaction at 22,000, this appears to be a new position rather than a partial adjustment.

Insider Trade Summary

Grant/Award: 22,000 shares

Grant/Award 1 txn

Insider Patel Naimish

Role Chief Medical Officer

Type	Security	Shares	Price	Value
Grant/Award	Restricted Stock Units	22,000	$0.00	$0.00

Holdings After Transaction: Restricted Stock Units — 22,000 contracts (Direct)

Footnotes (2)

1. F1. Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.
2. F2. This restricted stock unit award was granted on May 29, 2026 with respect to 22,000 Common Shares, with 100% of the shares vesting on November 29, 2028.

Key Figures

RSUs granted: 22,000 units RSU-to-share ratio: 1.0 share per unit Vesting date: November 29, 2028 +2 more

5 metrics

RSUs granted 22,000 units Restricted stock units granted on May 29, 2026

RSU-to-share ratio 1.0 share per unit Each RSU represents one common share

Vesting date November 29, 2028 100% of RSUs vest on this date

Post-grant RSU holdings 22,000 units Total restricted stock units following transaction

Transaction code A Grant, award, or other acquisition

Key Terms

Restricted Stock Units, contingent right, vesting, grant, award, or other acquisition

4 terms

Restricted Stock Units financial

"Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

contingent right financial

"Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares."

vesting financial

"100% of the shares vesting on November 29, 2028."

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did CRISPR Therapeutics (CRSP) report for Naimish Patel?

CRISPR Therapeutics reported a grant of 22,000 restricted stock units to Chief Medical Officer Naimish Patel. This equity award is compensation, not an open‑market share purchase, and represents a future right to receive common shares if vesting conditions are met.

How many CRISPR Therapeutics (CRSP) RSUs did the CMO receive and what do they represent?

The Chief Medical Officer received 22,000 restricted stock units. Each RSU represents a contingent right to receive one CRISPR Therapeutics common share, providing long-term equity exposure that vests over time rather than an immediate transfer of tradable stock.

When do Naimish Patel’s 22,000 CRISPR Therapeutics (CRSP) RSUs vest?

All 22,000 restricted stock units granted to Naimish Patel are scheduled to vest on November 29, 2028. Vesting on a single future date supports long-term retention and ties the CMO’s compensation to the company’s multi‑year performance outcomes.

Was the CRISPR Therapeutics (CRSP) insider transaction a stock purchase or a grant?

The transaction was a grant of restricted stock units, not an open‑market stock purchase. The Form 4 describes a compensation-related award classified as a grant, award, or other acquisition, with zero purchase price and future delivery of common shares upon vesting.

How many CRISPR Therapeutics (CRSP) RSUs does the CMO hold after this Form 4 transaction?

Following the reported transaction, Naimish Patel holds 22,000 restricted stock units directly. This figure reflects the newly granted award and represents his visible RSU position in this filing, all subject to vesting on November 29, 2028 under the grant terms.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/02/2026 - 05:41 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Patel Naimish

(Last) (First) (Middle)

C/O CRISPR THERAPEUTICS

105 WEST FIRST STREET

(Street)

BOSTON MASSACHUSETTS 02127

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CRISPR Therapeutics AG [ CRSP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/29/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	05/29/2026		A		22,000		(2)	(2)	Common Shares	22,000	$0	22,000	D

Explanation of Responses:

1. Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.

2. This restricted stock unit award was granted on May 29, 2026 with respect to 22,000 Common Shares, with 100% of the shares vesting on November 29, 2028.

	Elizabeth Ryland Waldinger, attorney-in-fact	06/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)